TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas

Anti-CD19 chimeric antigen receptor (CAR) T cells have shown impressive results in the treatment of relapsed/refractory aggressive large B-cell lymphomas (LBCLs). However, the prognostic value of the LBCL histological subtype in the context of CAR T-cell therapy is unclear. Here, we report the prognostic value of transformed indolent non-Hodgkin lymphoma (TriNHL; N = 110) confirmed by an expert pathological review (LYMPHOPATH) vs de novo LBCL (N = 391) in the context of CAR T-cell therapy from 4 centers of the French DESCAR-T registry. After 1:1 propensity score matching (n = 170, 85 patients with TriNHL and 85 patients with de novo LBCL), the median follow-up was 19.4 months (95% confidence interval [CI], 12.0-25.1) for patients with TriNHL and 18.5 months (95% CI, 13.8-24.8) for patients with LBCL. The 1-year progression-free survival rate was significantly better (55.8%; 95% CI, 43.6-66.4) in the TriNHL group than in the de novo LBCL group (31.7%; 95% CI, 21.4-42.6; hazard ratio, 0.54; 95% CI, 0.36-0.82; P = .0034). The best overall response rate and complete response rate were 82.4% and 63.5%, respectively, whereas they were 63.5% and 50.6%, respectively, for the TriNHL group compared with the de novo LBCL group. The 1-year overall survival was also longer in the TriNHL group than in the de novo LBCL group (72.1%, [95% CI, 59.6-81.4] vs 50.7%, [95% CI, 38.2-62.0]; P = .031). Similar findings were found via an inverse probability weighting statistical approach. No difference was observed in terms of toxicity. In conclusion, our matched-comparison study revealed a greater efficacy of CAR T-cell therapy, with a toxicity profile for patients with TriNHL comparable with that for patients with LBCL.

Authors

Institutions

Publication Details

Journal
Blood Advances
Published
2025-05-01
DOI
https://doi.org/10.1182/bloodadvances.2025015834
Citations
2
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
2.09

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas

Alexandra Traverse‐Glehen, Steven Le Gouill, Roberta Di Blasi, Pierre Stéphan et al.
2 citations
Blood Advances
CAR-T cell therapy research
2.09
article

TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas

Alexandra Traverse‐Glehen, Steven Le Gouill, Roberta Di Blasi, Pierre Stéphan, Roch Houot, Julien Calvani, Catherine Thiéblemont, Marie Donzel, François Lemonnier, Alexandra Marquet, Elsa Poullot, Emmanuel Bachy, Marie Parrens, Véronique Meignin, Jean Galtier, Pierre Sesques, Louise Roulin, François‐Xavier Gros, Vivien Dupont
article en
2 citations

Abstract

Anti-CD19 chimeric antigen receptor (CAR) T cells have shown impressive results in the treatment of relapsed/refractory aggressive large B-cell lymphomas (LBCLs). However, the prognostic value of the LBCL histological subtype in the context of CAR T-cell therapy is unclear. Here, we report the prognostic value of transformed indolent non-Hodgkin lymphoma (TriNHL; N = 110) confirmed by an expert pathological review (LYMPHOPATH) vs de novo LBCL (N = 391) in the context of CAR T-cell therapy from 4 centers of the French DESCAR-T registry. After 1:1 propensity score matching (n = 170, 85 patients with TriNHL and 85 patients with de novo LBCL), the median follow-up was 19.4 months (95% confidence interval [CI], 12.0-25.1) for patients with TriNHL and 18.5 months (95% CI, 13.8-24.8) for patients with LBCL. The 1-year progression-free survival rate was significantly better (55.8%; 95% CI, 43.6-66.4) in the TriNHL group than in the de novo LBCL group (31.7%; 95% CI, 21.4-42.6; hazard ratio, 0.54; 95% CI, 0.36-0.82; P = .0034). The best overall response rate and complete response rate were 82.4% and 63.5%, respectively, whereas they were 63.5% and 50.6%, respectively, for the TriNHL group compared with the de novo LBCL group. The 1-year overall survival was also longer in the TriNHL group than in the de novo LBCL group (72.1%, [95% CI, 59.6-81.4] vs 50.7%, [95% CI, 38.2-62.0]; P = .031). Similar findings were found via an inverse probability weighting statistical approach. No difference was observed in terms of toxicity. In conclusion, our matched-comparison study revealed a greater efficacy of CAR T-cell therapy, with a toxicity profile for patients with TriNHL comparable with that for patients with LBCL.

Blood AdvancesVol. 9(18)
Université de Bordeaux (FR), Inserm (FR), Université de Versailles Saint-Quentin-en-Yvelines (FR), Université Paris Cité (FR), Centre Hospitalier Universitaire de Bordeaux (FR), Université Rennes 2 (FR), Assistance Publique – Hôpitaux de Paris (FR), Hospices Civils de Lyon (FR), Bordeaux Population Health (FR), The Lymphoma Academic Research Organisation (FR), Hôpital Lyon Sud (FR), Hôpitaux Universitaires Henri-Mondor (FR), Hôpital Saint-Louis (FR), Lymphoma Study Association (FR), Centre Hospitalier Universitaire de Rennes (FR), Hôpital Albert-Chenevier (FR), Université de Rennes (FR), Institut Curie (FR)
Amgen, Bristol-Myers Squibb, Gilead Sciences, BeiGene, Incyte, Servier, Institut Servier
Good health and well-being
Openalex Percentile: Top 13%
CAR-T cell therapy research
2.09
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.